Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an ...
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia For the model, we used ...
Over 400,000 households in New York had their gas or electric shut off last year because of non-payment, surpassing recession-era totals.
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial For the model, we used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results